Gemopatrilat
Chemical compound
- None
- (6S)-Hexahydro-6-[(αS)-α-mercaptohydrocinnamido]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid
- 160135-92-2
- 9886079
- 8061752
- MU9089C77W
- D04312
- ChEMBL107747
- DTXSID901029484
- Interactive image
- CC1(CCC[C@@H](C(=O)N1CC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)S)C
InChI
- InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1
- Key:YRSVDSQRGBYVIY-GJZGRUSLSA-N
Gemopatrilat (INN)[1] is an experimental drug that was never marketed.[2] It acts as a vasopeptidase inhibitor.[3][4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).[5]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46" (PDF). World Health Organization. p. 200. Retrieved 2 March 2017.
- ^ "Gemopatrilat". AdisInsight.
Highest Development Phases: Discontinued
- ^ Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G (January 2003). "Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes". Kidney International. 63 (1): 64–71. doi:10.1046/j.1523-1755.2003.00708.x. PMID 12472769.
- ^ Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, et al. (June 2006). "Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans". Drug Metabolism and Disposition. 34 (6): 961–70. doi:10.1124/dmd.105.007500. PMID 16540589. S2CID 25629874.
- ^ Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM (May 2001). "In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat". Journal of Hypertension. 19 (5): 941–6. doi:10.1097/00004872-200105000-00015. PMID 11393678. S2CID 9162678.
- v
- t
- e
Antihypertensive drugs acting on the renin–angiotensin system (C09)
("-pril")
- Sulfhydryl-containing: Captopril
- Rentiapril
- Zofenopril (+nebivolol)
- Dicarboxylate-containing: Enalapril# (+lercanidipine, +nitrendipine)
- Benazepril (+amlodipine, +pimobendan)
- Cilazapril
- Delapril (+manidipine)
- Imidapril
- Lisinopril (+amlodipine, +HCT)
- Moexipril
- Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide)
- Quinapril (+HCT)
- Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine)
- Spirapril
- Temocapril
- Trandolapril (+verapamil)
- Phosphonate-containing: Ceronapril
- Fosinopril (+HCT)
- Other/ungrouped: Alacepril
("-sartan")
- Azilsartan
- Candesartan (+amlodipine, +amlodipine and HCT)
- Eprosartan
- Fimasartan
- Irbesartan (+amlodipine, +amlodipine and HCT, +HCT)
- Losartan (+amlodipine, +HCT)
- Olmesartan (+amlodipine, +amlodipine and HCT, +HCT)
- Tasosartan§
- Telmisartan (+amlodipine, +amlodipine and HCT, +HCT)
- Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
("-kiren")
- Gemopatrilat
- Ilepatril
- Omapatrilat
- Sampatrilat
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e